The landscape of clinical trials for new weight-loss medications is facing an unprecedented challenge: patients are leaving studies in droves, disrupting a fundamental pillar of drug development – the blinding process. This exodus is directly linked to the growing availability of highly effective obesity treatments already on the market, such as Eli Lilly & Co.’s Zepbound and Novo Nordisk A/S’s Wegovy (available as both an injection and an oral medication).
The Blinding Problem
Traditionally, clinical trials rely on a “blinded” approach, where neither the patient nor the doctor knows whether the participant is receiving the actual drug or a placebo. This is crucial for ensuring unbiased results. However, with potent weight-loss drugs now readily accessible and becoming more affordable, participants in trials who aren’t experiencing significant weight loss are quickly realising they’ve been assigned a placebo. This realisation offers little incentive to remain in a study that isn’t delivering the desired outcome.
“Right now, retention is challenging,” commented Barbara McGowan, a consultant in diabetes and endocrinology based in London and an investigator for several obesity-drug trials. This dynamic shift is a clear indicator of the rapid pace of innovation in the weight-loss sector, with an impressive 190 potential new medications currently under development.
Patient Perspectives and the Draw of Approved Treatments
The willingness of patients to leave trials is amplified by the fact that they can now access approved obesity medications. In earlier generations of studies, participants often lacked alternative options and were at least receiving support for diet and exercise.
Raymond Stevens, CEO of Structure Therapeutics Inc., which is developing an experimental pill designed to compete with oral treatments from Lilly and Novo, explained, “People learn pretty quickly whether they’re on placebo or not. It’s adding a challenge to conducting clinical trials.”
One such patient, a 57-year-old from New England who preferred to remain anonymous to protect his medical privacy, shared his experience. He has been participating in a trial for Lilly’s next-generation injection, retatrutide. He initially joined because he believed he didn’t meet the criteria for insurance coverage of Wegovy or Zepbound. He managed to lose approximately 45 pounds in less than a year by strictly adhering to a calorie-restricted diet. “I could tell the only reason I was dropping it was because I was being really vigilant about the diet,” he stated. He didn’t feel any discernible effect from the study drug, noting that his appetite remained unchanged, a stark contrast to potential side effects like nausea or vomiting. “My appetite was still 100% the same. Over time, my weight drifted back up again and it became pretty clear I was on the placebo.”
However, his situation is now evolving. With his insurance potentially covering Wegovy due to its demonstrated cardiovascular benefits, he intends to withdraw from the retatrutide study if this becomes a reality.
The Ripple Effect on Trial Integrity
Experiences like Tom’s are directly undermining the blinding process, a cornerstone of reliable clinical trials. McGowan highlighted a significant risk: the patients remaining in the placebo arm may be those who are already achieving weight loss through diet and exercise alone. Since these lifestyle changes are not effective for a large proportion of individuals with obesity, this could skew the study results, making the investigational drugs appear less effective than they truly are.
While patient dropouts from early weight-loss drug trials due to awareness of receiving a placebo were not unheard of, experts suggest that the numbers are now escalating. This is attributed to the increased potency of newer drugs and greater public awareness.
“This is a change,” acknowledged Louis Aronne, an obesity physician at Weill Cornell Medicine who has conducted clinical trials for Lilly and other pharmaceutical companies. “It’s something we have to deal with.”
Unprecedented Challenges and Social Media’s Role
Adding another layer of complexity, some patients on placebo are reportedly seeking out weight-loss drugs from external sources while still enrolled in trials. This practice, as noted by Aronne, could further distort the findings.
Lilly encountered this directly with its highly anticipated oral medication, orforglipron. In a significant trial, 6.2% of patients in the placebo group discontinued their participation due to dissatisfaction with their weight loss. An additional 2.5% began seeking alternative methods for weight reduction, which, in some instances, involved other obesity medications. A Lilly spokesperson confirmed that while this was technically not permitted, participants could remain in the trial if they ceased taking the study drug.
Kenneth Custer, president of Lilly’s cardiometabolic health unit, described the situation as drugs becoming “rather, sort of, de-blinded.” He elaborated, “You’re sort of asking patients to sign up for a 72-week experience where they may very well be randomized to placebo. It’s a long time to go without efficacy.”
The pervasive influence of social media, particularly platforms like Reddit, has further exacerbated the issue. The intense hype surrounding these medications has led to real-time discussions about clinical trials, a phenomenon that is entirely new in drug development. Stevens pointed to discussions on Reddit concerning orforglipron, remarking, “People aren’t supposed to be talking about these things, but it was on Reddit — during the trial.”
Adapting Trial Designs for the Future
In response to these evolving challenges, companies are reassessing their trial methodologies. Roche Holding AG, for instance, is contemplating offering patients the option of an extended trial period. This would provide participants who received the placebo an opportunity to access the experimental weight-loss drug. While the specifics are still being finalised, Roche believes this approach is crucial for patient recruitment and retention.
“We’re doing everything we can to keep people engaged and into the trials,” stated Manu Chakravarthy, Roche’s head of cardiovascular, renal and metabolism product development.
Beyond the Placebo
Another potential strategy involves designing trials that directly compare new compounds against existing, approved weight-loss medicines, rather than using a placebo. This approach is already standard practice for severe conditions like cancer. However, regulatory bodies like the US Food and Drug Administration (FDA) and their European counterparts still mandate placebo comparisons for obesity treatments. The FDA and the European Medicines Agency did not immediately respond to requests for comment.
“I think we’re going to see an evolution of how clinical trials are executed and that’s for good reasons,” Stevens of Structure Therapeutics commented. Lilly has expressed openness to such changes, according to Custer. Novo Nordisk, meanwhile, highlighted its practice of offering counselling and follow-up support within its trials, which assists some patients on placebo in achieving lifestyle changes and weight loss.
The historical context of obesity, where it has only recently gained recognition as a disease after many individuals have struggled with weight management for years, adds another layer of complexity. Amber Huett-Garcia, a board member of the World Obesity Federation, observed, “It almost feels like the definition of obesity and how we understand it as a disease has not made it into clinical-trial standards of care.” This evolving understanding of obesity as a chronic disease, rather than a matter of willpower, is prompting a necessary re-evaluation of how clinical trials are conducted in this rapidly advancing field.
